comparemela.com

Latest Breaking News On - University of virginia comprehensive cancer center - Page 1 : comparemela.com

New combination treatment offers hope for older patients with mantle cell lymphoma

The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients over the age of 60 with mantle cell lymphoma (MCL) who received bendamustine and rituximab, a standard chemo-immunotherapy treatment, along with venetoclax, which is investigational in this setting.

San-diego
California
United-states
American
Craiga-portell
Genentech
University-of-virginia-comprehensive-cancer-center
American-society-of-hematology
Member-of-the-roche-group
American-society
Virginia-comprehensive-cancer

vimarsana © 2020. All Rights Reserved.